Incyte

ABOUT

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs through the discovery, development and commercialization of proprietary therapeutics.

Since 2002, Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients and make a difference in healthcare. Incyte’s unique expertise in medicinal chemistry and biology has enabled us to establish a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity, including 24 clinical compounds in development.

Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. We have more than 2,500 employees, including more than 1,000 world-class scientists, who are committed to discovering first-in-class medicines for patients who previously had limited treatment options.

For more information about Incyte, please visit us at www.Incyte.com. Follow Incyte on X, LinkedIn, Facebook and Instagram.

1801 Augustine Cut-off, Wilmington, DE 19803

Visit website

NEWS

FDA

FDA Approves MorphoSys and Incyte’s DLBCL Drug Monjuvi

Eight months after inking a collaboration deal, MorphoSys and Incyte won approval for Monjuvi for adult patients with relapsed or refractory diffuse large B-cell lymphoma.

August 3, 2020

2 min read

Alex Keown

BioCapital

Clinical Catch-Up: July 20-24

It was a busy week for clinical trial news, with some very important early-stage trial data for various COVID-19 vaccines. Here’s a look.

July 24, 2020

8 min read

Mark Terry

Jakafi showed positive results in phase III graft-

Drug Development

Incyte’s Jakafi Hits Mark in Phase III Graft-Versus-Host Disease Trial

Jakafi hit the mark, meeting the trial’s primary endpoint of superior overall response rate (ORR) at Week 24 compared to best available therapy (BAT).

July 23, 2020

3 min read

Mark Terry

Policy

FDA Action Alert: Evofem, Sanofi, Regeneron and Incyte

Heading into the first week after Memorial Day, which in the U.S. marks the typical beginning of summer, the U.S. Food and Drug Administration has a number of drug approvals on the calendar. Here’s a look.

May 22, 2020

3 min read

Mark Terry

Bio NC

Clinical Catch-Up: May 11-15

Clinical trial updates not related to COVID-19 are on the upswing, partly because some companies are announcing trial information ahead of the upcoming American Society of Clinical Oncology virtual meeting being held at the end of the month. Here’s a look.

May 15, 2020

12 min read

Mark Terry

Policy

Biopharma Update on the Novel Coronavirus: May 5

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 5, 2020.

May 5, 2020

6 min read

BioSpace Editorial Staff

FDA

FDA Approves Incyte’s Pemazyre for Rare Bile Duct Cancer

The U.S. Food and Drug Administration (FDA) approved Incyte’s Pemazyre (pemigatinib) for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.

April 20, 2020

3 min read

Mark Terry